Company intelligence / Profile preview

OnCore Biopharma

Ownership: Private
Development stage: Other

Overview

OnCore Biopharma was a biopharmaceutical company focused on developing all-oral treatments targeting a cure for chronic hepatitis B virus infection. The company ceased independent operations after merging with Tekmira Pharmaceuticals in January 2015, becoming a wholly-owned subsidiary. At the time of the merger announcement, the implied market value of the combined entity was approximately $750 million.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on OnCore Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OnCore Biopharma.

Explore the full profile